You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAcarbose
Accession NumberDB00284  (APRD00656)
TypeSmall Molecule
GroupsApproved, Investigational
Description

An inhibitor of alpha glucosidase that retards the digestion and absorption of carbohydrates in the small intestine and hence reduces the increase in blood-glucose concentrations after a carbohydrate load. It is given orally to non-insulin dependent diabetes mellitus patients where diet modification or oral hypoglycemic agents do not control their condition. (From Martindale The Extra Pharmacopoeia, 31st ed)

Structure
Thumb
Synonyms
SynonymLanguageCode
AcarbosaNot AvailableNot Available
AcarboseNot AvailableNot Available
AcarbosumNot AvailableNot Available
GlucobayNot AvailableNot Available
PrecoseNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Precosetablet50 mgoralAphena Pharma Solutions Tennessee, Llc2008-01-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet25 mgoralAlvogen, Inc.2008-01-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet50 mgoralAlvogen, Inc.2008-01-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet100 mgoralAlvogen, Inc.2008-01-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Precosetablet50 mgoralBayer Health Care Pharmaceuticals Inc.2008-01-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Precosetablet100 mgoralBayer Health Care Pharmaceuticals Inc.2008-01-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Precosetablet25 mgoralBayer Health Care Pharmaceuticals Inc.2008-01-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Precosetablet25 mgoralPhysicians Total Care, Inc.2007-11-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glucobaytablet100 mgoralBayer IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Glucobaytablet50 mgoralBayer IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acarbosetablet25 mgoralRoxane Laboratories, Inc2008-05-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet50 mgoralRoxane Laboratories, Inc2008-05-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet100 mgoralRoxane Laboratories, Inc2008-05-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet25 mgoralGlobal Pharmaceuticals, Division of Impax Laboratories, Inc.2009-05-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet50 mgoralGlobal Pharmaceuticals, Division of Impax Laboratories, Inc.2009-05-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet100 mgoralGlobal Pharmaceuticals, Division of Impax Laboratories, Inc.2009-05-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet25 mgoralMylan Pharmaceuticals Inc.2011-01-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet50 mgoralMylan Pharmaceuticals Inc.2011-01-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet100 mgoralMylan Pharmaceuticals Inc.2011-01-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet25 mgoralActavis Pharma, Inc.2008-05-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet50 mgoralActavis Pharma, Inc.2008-05-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet100 mgoralActavis Pharma, Inc.2008-05-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet25 mgoralHeritage Pharmaceuticals Inc.2012-07-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet50 mgoralHeritage Pharmaceuticals Inc.2012-07-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet100 mgoralHeritage Pharmaceuticals Inc.2012-07-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet25 mgoralAv Kare, Inc.2013-12-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet50 mgoralAv Kare, Inc.2013-12-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet100 mgoralAv Kare, Inc.2013-12-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet25 mgoralLibertas Pharma, Inc.2011-07-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet50 mgoralLibertas Pharma, Inc.2011-07-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet100 mgoralLibertas Pharma, Inc.2011-07-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet25 mgoralPhysicians Total Care, Inc.2008-10-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet50 mgoralPd Rx Pharmaceuticals, Inc.2008-05-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet25 mgoralStrides Arcolab Limited2011-07-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet50 mgoralStrides Arcolab Limited2011-07-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet100 mgoralStrides Arcolab Limited2011-07-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet25 mgoralVirtus Pharmaceuticals LLC2015-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet50 mgoralVirtus Pharmaceuticals LLC2015-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet100 mgoralVirtus Pharmaceuticals LLC2015-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet25 mgoralVirtus Pharmaceuticals LLC2013-10-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet50 mgoralVirtus Pharmaceuticals LLC2013-10-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Acarbosetablet100 mgoralVirtus Pharmaceuticals LLC2013-10-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
PrandaseBayer AG
Brand mixturesNot Available
SaltsNot Available
CategoriesNot Available
CAS number56180-94-0
WeightAverage: 645.6048
Monoisotopic: 645.248013577
Chemical FormulaC25H43NO18
InChI KeyXUFXOAAUWZOOIT-JMPDRRIHSA-N
InChI
InChI=1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12+,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-/m1/s1
IUPAC Name
(2R,3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-{[(1S,4S,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-(hydroxymethyl)oxane-2,3,4-triol
SMILES
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@H](O)[C@H](O)[C@H]1O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as oligosaccharides. These are carbohydrates made up of 3 to 10 monosaccharide units linked to each other through glycosidic bonds.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassOligosaccharides
Direct ParentOligosaccharides
Alternative Parents
Substituents
  • Oligosaccharide
  • Glucosamine
  • O-glycosyl compound
  • Glycosyl compound
  • Cyclitol derivative
  • Amino saccharide
  • Oxane
  • Secondary alcohol
  • Polyol
  • Hemiacetal
  • 1,2-diol
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Acetal
  • Hydrocarbon derivative
  • Primary alcohol
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor treatment and management of diabetes type II (used in combination therapy as a second or third line agent)
PharmacodynamicsUsed to reduce blood gluose in patients with type 2 diabetes. Acarbose is a complex oligosaccharide that delays the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals. Acarbose binds to and inhibits alpha amylase and alpha-gluocside hydrolases. In diabetic patients, this enzyme inhibition results in a delayed glucose absorption and a lowering of postprandial hyperglycemia.
Mechanism of actionAcarbose reversibly bind to pancreatic alpha-amylase and membrane-bound intestinal alpha-glucoside hydrolases. These enzymes inhibit hydrolysis of complex starches to oligosaccharides in the lumen of the small intestine and hydrolysis of oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the brush border of the small intestine.
AbsorptionExtremely low bioavailability. Less than 2% of an oral dose of acarbose was absorbed as active drug. Peak plasma concentrations of the active drug were achieved 1 hour after dosing. Drug accumulation does not occur with multiple doses.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Acarbose is only metabolized within the gastrointestinal tract by intestinal bacteria and also digestive enzymes to a lesser extent. 4-methylpyrogallol derivatives (sulfate, methyl, and glucuronide conjugates) are the major metabolites. One metabolite (formed by cleavage of a glucose molecule from acarbose) also has alpha-glucosidase inhibitory activity.

Route of eliminationThe fraction of acarbose that is absorbed as intact drug is almost completely excreted by the kidneys. A fraction of the metabolites (approximately 34% of the dose) was absorbed and subsequently excreted in the urine. The active metabolite is excreted into the urine and accounts for less than 2% of the total administered dose. When given intravenously, 89% of the dose was excreted into the urine as the active drug. When given orally, less than 2% of the oral dose was recovered into the urine as active (parent compound and active metabolite) drug.
Half lifeHealthy volunteers = 2 hours
ClearanceNot Available
ToxicityGastrointestinal symptoms are the most common reactions to acarbose.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8467
Blood Brain Barrier-0.9723
Caco-2 permeable-0.725
P-glycoprotein substrateSubstrate0.5316
P-glycoprotein inhibitor IInhibitor0.5421
P-glycoprotein inhibitor IINon-inhibitor0.8656
Renal organic cation transporterNon-inhibitor0.8647
CYP450 2C9 substrateNon-substrate0.7581
CYP450 2D6 substrateNon-substrate0.8505
CYP450 3A4 substrateNon-substrate0.5683
CYP450 1A2 substrateNon-inhibitor0.8791
CYP450 2C9 substrateNon-inhibitor0.8677
CYP450 2D6 substrateNon-inhibitor0.8974
CYP450 2C19 substrateNon-inhibitor0.8392
CYP450 3A4 substrateNon-inhibitor0.986
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7163
Ames testNon AMES toxic0.8054
CarcinogenicityNon-carcinogens0.967
BiodegradationNot ready biodegradable0.6447
Rat acute toxicity1.4610 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8586
hERG inhibition (predictor II)Non-inhibitor0.8288
Pharmacoeconomics
Manufacturers
  • Impax laboratories inc
  • Roxane laboratories inc
  • Watson laboratories inc
  • Bayer healthcare pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral100 mg
Tabletoral25 mg
Tabletoral50 mg
Prices
Unit descriptionCostUnit
Acarbose 100 100 mg tablet Bottle120.62USD bottle
Acarbose 100 50 mg tablet Bottle100.71USD bottle
Acarbose 100 25 mg tablet Bottle93.54USD bottle
Precose 100 mg tablet1.28USD tablet
Acarbose 100 mg tablet1.17USD tablet
Precose 50 mg tablet1.11USD tablet
Precose 25 mg tablet1.01USD tablet
Acarbose 25 mg tablet0.91USD tablet
Acarbose 50 mg tablet0.88USD tablet
Glucobay 100 mg Tablet0.4USD tablet
Glucobay 50 mg Tablet0.29USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-6.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility148.0 mg/mLALOGPS
logP-2.7ALOGPS
logP-7.6ChemAxon
logS-0.64ALOGPS
pKa (Strongest Acidic)11.23ChemAxon
pKa (Strongest Basic)7.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count19ChemAxon
Hydrogen Donor Count14ChemAxon
Polar Surface Area321.17 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity137.6 m3·mol-1ChemAxon
Polarizability62.39 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Anneliese Crueger, Wolfgang Piepersberg, Jurgen Distler, Ansgar Stratmann, “Acarbose biosynthesis genes from actinoplanes sp., process for the isolation thereof and the use thereof.” U.S. Patent US5753501, issued December, 1977.

US5753501
General Reference
  1. Clissold SP, Edwards C: Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1988 Mar;35(3):214-43. Pubmed
  2. FDA label
External Links
ATC CodesA10BF01
AHFS Codes
  • 68:20.02
PDB EntriesNot Available
FDA labelDownload (268 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcetohexamideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
Acetylsalicylic acidMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
BuforminAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
ChlorpropamideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
DigoxinAcarbose may decrease the serum concentration of Digoxin.
DihydrotestosteroneMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.
ExenatideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
GliclazideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
GlimepirideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
GlipizideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
Glucagon recombinantAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
GlyburideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin AspartAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin GlargineAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin LisproAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin, isophaneAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin, porcineAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
MitiglinideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
NateglinideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
NeomycinMay enhance the adverse/toxic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose.
OxandroloneMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.
PegvisomantMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
PhenforminAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
PioglitazoneAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
RepaglinideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
Salicylate-sodiumMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
SulodexideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
TestosteroneMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.
TolbutamideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
Food Interactions
  • Take with food, at beginning of each meal.

Targets

1. Maltase-glucoamylase, intestinal

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Maltase-glucoamylase, intestinal O43451 Details

References:

  1. Okumiya T, Keulemans JL, Kroos MA, Van der Beek NM, Boer MA, Takeuchi H, Van Diggelen OP, Reuser AJ: A new diagnostic assay for glycogen storage disease type II in mixed leukocytes. Mol Genet Metab. 2006 May;88(1):22-8. Epub 2005 Dec 15. Pubmed
  2. Zhang H, Kallwass H, Young SP, Carr C, Dai J, Kishnani PS, Millington DS, Keutzer J, Chen YT, Bali D: Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med. 2006 May;8(5):302-6. Pubmed
  3. Gelb MH, Turecek F, Scott CR, Chamoles NA: Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):397-404. Pubmed
  4. Yamagishi S, Matsui T, Ueda S, Fukami K, Okuda S: Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders. Curr Drug Metab. 2009 Feb;10(2):159-63. Pubmed
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Lysosomal alpha-glucosidase

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Lysosomal alpha-glucosidase P10253 Details

References:

  1. Salehi A, Fan BG, Ekelund M, Nordin G, Lundquist I: TPN-evoked dysfunction of islet lysosomal activity mediates impairment of glucose-stimulated insulin release. Am J Physiol Endocrinol Metab. 2001 Jul;281(1):E171-9. Pubmed
  2. Li Y, Scott CR, Chamoles NA, Ghavami A, Pinto BM, Turecek F, Gelb MH: Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem. 2004 Oct;50(10):1785-96. Epub 2004 Aug 3. Pubmed
  3. Lundquist I, Panagiotidis G: The relationship of islet amyloglucosidase activity and glucose-induced insulin secretion. Pancreas. 1992;7(3):352-7. Pubmed
  4. Zhang H, Kallwass H, Young SP, Carr C, Dai J, Kishnani PS, Millington DS, Keutzer J, Chen YT, Bali D: Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med. 2006 May;8(5):302-6. Pubmed
  5. Gelb MH, Turecek F, Scott CR, Chamoles NA: Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):397-404. Pubmed
  6. Lullmann-Rauch R, Watermann D: Fusion of storage lysosomes in experimental lipidosis and glycogenosis. Exp Mol Pathol. 1987 Feb;46(1):136-43. Pubmed
  7. Bourbon JR, Doucet E, Rieutort M: Role of alpha-glucosidase in fetal lung maturation. Biochim Biophys Acta. 1987 Jan 13;917(1):203-10. Pubmed
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

3. Sucrase-isomaltase, intestinal

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Sucrase-isomaltase, intestinal P14410 Details

References:

  1. Juretic D, Bernik S, Cop L, Hadzija M, Petlevski R, Lukac-Bajalo J: Short-term effect of acarbose on specific intestinal disaccharidase activities and hyperglycaemia in CBA diabetic mice. J Anim Physiol Anim Nutr (Berl). 2003 Aug;87(7-8):263-8. Pubmed
  2. Meyer H, Wieczorek H, Zeiske W: K+ transport in the caterpillar intestine epithelium: role of osmolytes for the K+-secretory capacity of the tobacco hornworm midgut. J Comp Physiol [B]. 2004 Oct;174(7):527-39. Epub 2004 Aug 20. Pubmed
  3. Karley AJ, Ashford DA, Minto LM, Pritchard J, Douglas AE: The significance of gut sucrase activity for osmoregulation in the pea aphid, Acyrthosiphon pisum. J Insect Physiol. 2005 Dec;51(12):1313-9. Epub 2005 Sep 15. Pubmed
  4. Samulitis BK, Goda T, Lee SM, Koldovsky O: Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine. Drugs Exp Clin Res. 1987;13(8):517-24. Pubmed
  5. Newbrun E, Hoover CI, Walker GJ: Inhibition by acarbose, nojirimycin and 1-deoxynojirimycin of glucosyltransferase produced by oral streptococci. Arch Oral Biol. 1983;28(6):531-6. Pubmed

4. Pancreatic alpha-amylase

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Pancreatic alpha-amylase P04746 Details

References:

  1. Jonas L, Mikkat U, Lehmann R, Schareck W, Walzel H, Schroder W, Lopp H, Pussa T, Toomik P: Inhibitory effects of human and porcine alpha-amylase on CCK-8-stimulated lipase secretion of isolated rat pancreatic acini. Pancreatology. 2003;3(4):342-8. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:09